CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer (NCT07704801) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer
Egypt300 participantsStarted 2021-01-01
Plain-language summary
This study is a retrospective review aimed at evaluating the real-world outcomes and clinical efficacy of CDK4/6 inhibitors (such as Palbociclib, Ribociclib, or Abemaciclib) in patients diagnosed with metastatic luminal A and luminal B breast cancer. The study will assess how patients responded to these treatments based on their specific breast cancer subtype (Luminal A vs. Luminal B) by reviewing their medical records.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* patients who are more than 18 years old at time of diagnosis and less than 80 years
* metastatic breast cancer luminal A and luminal B of either sex
Exclusion Criteria:
* patients diagnosed with double malignancy
* patients with incomplete medical records
* patients with organ failure
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is listed as 'active, not recruiting,' which means they're no longer accepting new patients — can you help me understand if there's a similar study involving CDK4/6 inhibitors for HR-positive metastatic breast cancer that I might still be able to join?
2Since this study's phase is listed as 'NA,' it's not a standard Phase 1, 2, or 3 trial — does that mean it's more of an observational or registry study, and if so, what does that mean for my care compared to a traditional treatment trial?
3The main thing this trial is tracking is progression-free survival, meaning how long before the disease gets worse — based on what's already known about CDK4/6 inhibitors, how does that outcome typically compare to other treatment options you'd consider for my situation?
4CDK4/6 inhibitors are a class of drugs, not a single medication — if a study like this were relevant to me, which specific drug or combination would be involved, and are there differences in side effects or schedules between them that I should know about?
5Since this trial is no longer enrolling, would the standard-of-care use of CDK4/6 inhibitors for HR-positive metastatic breast cancer be an option for me right now, without needing to be in a trial at all?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
progression free survival
Timeframe: Up to 4 years أو From initiation of CDK4/6 inhibitor therapy to disease progression or death, up to 4 years.
2
Progression-Free Survival (PFS)
Timeframe: From the date of therapy initiation up to 4 yrs
3
Progression-Free Survival (PFS)
Timeframe: From the date of therapy initiation up to 4 years (the period of retrospective medical records review).